{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269492","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.955688+00:00","generated_at":"2026-05-16T23:23:11.258790+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC","bullets":["Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.","Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.","Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.","Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.","Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269492","json":"https://secwatch.observer/filing/0001193125-25-269492.json","markdown":"https://secwatch.observer/filing/0001193125-25-269492.md","text":"https://secwatch.observer/filing/0001193125-25-269492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/0001193125-25-269492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/crdf-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:23:11.258790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}